The study analyzed medical records from more than 6,800 people diagnosed with colon cancer across University of California Health facilities
And the medical community has increasingly come to understand the many biological, genetic, environmental, psychological, and social factors that impact weight management
Start one product at a time to ensure that you are not sensitive.
Who Should Pay Attention to This Research This trial is most immediately relevant to: Older adults with known risk factors for cognitive decline particularly those with obesity, type 2 diabetes, high blood pressure, or cardiovascular disease who are also candidates for GLP-1 therapy Researchers and clinicians working at the intersection of metabolic health and cognitive aging People currently taking GLP-1 medications for diabetes or obesity who have wondered whether the drugs may offer cognitive benefits Caregivers and family members of older adults who are monitoring cognitive health and looking for potential preventive strategies Symptoms and Warning Signs to Watch For The PROTECT-Cog Study is designed for prevention it targets people who are at risk for cognitive decline but have not yet been diagnosed with dementia
Novo Nordisk price cuts create competitive headwinds The primary factor driving recent weakness stems from escalating price competition in GLP-1 obesity treatments, where Hims & Hers is attempting to establish a foothold
